These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 3735134)
41. Drug disposition in obese humans. An update. Abernethy DR; Greenblatt DJ Clin Pharmacokinet; 1986; 11(3):199-213. PubMed ID: 3524955 [TBL] [Abstract][Full Text] [Related]
42. Rat insulin turnover in vivo. Cañas X; Fernández-López JA; Ardévol A; Adán C; Esteve M; Rafecas I; Remesar X; Alemany M Endocrinology; 1995 Sep; 136(9):3871-6. PubMed ID: 7649094 [TBL] [Abstract][Full Text] [Related]
43. Water balance in Zucker obese rats. Rafecas I; Esteve M; Fernández-López JA; Remesar X; Alemany M Comp Biochem Physiol Comp Physiol; 1993 Apr; 104(4):813-8. PubMed ID: 8097986 [TBL] [Abstract][Full Text] [Related]
44. Increased sensitivity of Zucker obese rats to naloxone is present at weaning. McLaughlin CL; Baile CA Physiol Behav; 1984 Jun; 32(6):929-33. PubMed ID: 6093166 [TBL] [Abstract][Full Text] [Related]
45. Lidocaine disposition in obesity. Abernethy DR; Greenblatt DJ Am J Cardiol; 1984 Apr; 53(8):1183-6. PubMed ID: 6702701 [TBL] [Abstract][Full Text] [Related]
46. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Abernethy DR; Greenblatt DJ; Smith TW Am Heart J; 1981 Oct; 102(4):740-4. PubMed ID: 7282520 [TBL] [Abstract][Full Text] [Related]
47. Thiopental disposition in lean and obese patients undergoing surgery. Jung D; Mayersohn M; Perrier D; Calkins J; Saunders R Anesthesiology; 1982 Apr; 56(4):269-74. PubMed ID: 7065435 [TBL] [Abstract][Full Text] [Related]
48. The effect of obesity on apparent volume of distribution of theophylline. Rohrbaugh TM; Danish M; Ragni MC; Yaffe SJ Pediatr Pharmacol (New York); 1982; 2(1):75-83. PubMed ID: 7110759 [TBL] [Abstract][Full Text] [Related]
49. Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. Pfeffer M; Gaver RC; Van Harken DR J Pharm Sci; 1980 Apr; 69(4):398-403. PubMed ID: 7373533 [TBL] [Abstract][Full Text] [Related]
50. Clinical pharmacokinetics of drugs in obesity. An update. Cheymol G Clin Pharmacokinet; 1993 Aug; 25(2):103-14. PubMed ID: 8403734 [TBL] [Abstract][Full Text] [Related]
51. Lack of interaction between verapamil and cimetidine. Abernethy DR; Schwartz JB; Todd EL Clin Pharmacol Ther; 1985 Sep; 38(3):342-9. PubMed ID: 4028631 [TBL] [Abstract][Full Text] [Related]
52. Altered drug-serum protein binding in the genetically obese Zucker rat. Benedek IH; Blouin RA; McNamara PJ J Pharm Sci; 1985 Aug; 74(8):837-40. PubMed ID: 4032266 [TBL] [Abstract][Full Text] [Related]
53. Prediction of steady-state verapamil plasma concentrations in children and adults. Wagner JG; Rocchini AP; Vasiliades J Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504 [TBL] [Abstract][Full Text] [Related]
55. The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. Giacomini JC; Nelson WL; Theodore L; Wong FM; Rood D; Giacomini KM J Cardiovasc Pharmacol; 1985; 7(3):469-75. PubMed ID: 2410676 [TBL] [Abstract][Full Text] [Related]
56. Computation of the effective body mass for metabolic studies of lean and obese rats. Refinetti R Metabolism; 1989 Aug; 38(8):763-6. PubMed ID: 2761413 [TBL] [Abstract][Full Text] [Related]